Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease
- PMID: 9468467
- DOI: 10.1056/NEJM199802193380804
Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease
Erratum in
- N Engl J Med 1998 Apr 30;338(18):1325
Abstract
Background: The epsilon4 allele of the gene encoding apolipoprotein E (APOE) is strongly associated with Alzheimer's disease, but its value in the diagnosis remains uncertain.
Methods: We reviewed clinical diagnoses and diagnoses obtained at autopsy in 2188 patients referred to 1 of 26 Alzheimer's disease centers for evaluation of dementia. The sensitivity and specificity of the clinical diagnosis or the presence of an APOE epsilon4 allele were calculated, with pathologically confirmed Alzheimer's disease used as the standard. The added value of the APOE genotype was estimated with pretest and post-test probabilities from multivariate analyses to generate receiver-operating-characteristic curves plotting sensitivity against the false positive rate.
Results: Of the 2188 patients, 1833 were given a clinical diagnosis of Alzheimer's disease, and the diagnosis was confirmed pathologically in 1770 patients at autopsy. Sixty-two percent of patients with clinically diagnosed Alzheimer's disease, as compared with 65 percent of those with pathologically confirmed Alzheimer's disease, had at least one APOE epsilon4 allele. The sensitivity of the clinical diagnosis was 93 percent, and the specificity was 55 percent, whereas the sensitivity and specificity of the APOE epsilon4 allele were 65 and 68 percent, respectively. The addition of information about the APOE genotype increased the overall specificity to 84 percent in patients who met the clinical criteria for Alzheimer's disease, although the sensitivity decreased. The improvement in specificity remained statistically significant in the multivariate analysis after adjustment for differences in age, clinical diagnosis, sex, and center.
Conclusions: APOE genotyping does not provide sufficient sensitivity or specificity to be used alone as a diagnostic test for Alzheimer's disease, but when used in combination with clinical criteria, it improves the specificity of the diagnosis.
Comment in
- ACP J Club. 1998 Sep-Oct;129(2):48
Similar articles
-
Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer's Disease.Ann Neurol. 1997 Sep;42(3):319-25. doi: 10.1002/ana.410420308. Ann Neurol. 1997. PMID: 9307253 Clinical Trial.
-
[Dementia and cognitive impairment pattern: its association with epsilon4 allele of apolipoprotein E gene].Rev Neurol. 2004 May 1-15;38(9):801-7. Rev Neurol. 2004. PMID: 15152345 Spanish.
-
CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.Neurosci Lett. 2008 Aug 1;440(2):145-9. doi: 10.1016/j.neulet.2008.05.076. Epub 2008 May 24. Neurosci Lett. 2008. PMID: 18555606
-
Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention.Alzheimers Dement. 2011 Jul;7(4):e118-23. doi: 10.1016/j.jalz.2010.06.003. Epub 2011 Jun 14. Alzheimers Dement. 2011. PMID: 21665554 Review.
-
Alzheimer's disease: clinical implications of the apolipoprotein E genotype.Neurology. 1997 May;48(5 Suppl 6):S30-4. doi: 10.1212/wnl.48.5_suppl_6.30s. Neurology. 1997. PMID: 9153158 Review.
Cited by
-
Use of florbetapir-PET for imaging beta-amyloid pathology.JAMA. 2011 Jan 19;305(3):275-83. doi: 10.1001/jama.2010.2008. JAMA. 2011. PMID: 21245183 Free PMC article.
-
The Role of PICALM in Alzheimer's Disease.Mol Neurobiol. 2015 Aug;52(1):399-413. doi: 10.1007/s12035-014-8878-3. Epub 2014 Sep 4. Mol Neurobiol. 2015. PMID: 25186232 Review.
-
2024 Alzheimer's disease facts and figures.Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30. Alzheimers Dement. 2024. PMID: 38689398 Free PMC article.
-
The Janus-like Association between Proton Pump Inhibitors and Dementia.Curr Alzheimer Res. 2021;18(6):453-469. doi: 10.2174/1567205018666210929144740. Curr Alzheimer Res. 2021. PMID: 34587884 Free PMC article.
-
Polygenic risk discriminates Lewy body dementia from Alzheimer's disease.Alzheimers Dement. 2025 Feb;21(2):e14381. doi: 10.1002/alz.14381. Epub 2025 Jan 24. Alzheimers Dement. 2025. PMID: 39853853 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous